Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation by N. Ferri et al.
Corsini
Nicola Ferri, Giulia Colombo, Corrado Ferrandi, Elaine W. Raines, Bodo Levkau and Alberto
Polymerized Collagen by Inhibiting Rac1 Activation
Simvastatin Reduces MMP1 Expression in Human Smooth Muscle Cells Cultured on
Print ISSN: 1079-5642. Online ISSN: 1524-4636 
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Greenville Avenue, Dallas, TX 75231
is published by the American Heart Association, 7272Arteriosclerosis, Thrombosis, and Vascular Biology 
doi: 10.1161/ATVBAHA.107.139881
2007;
2007;27:1043-1049; originally published online February 15,Arterioscler Thromb Vasc Biol. 
 http://atvb.ahajournals.org/content/27/5/1043
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://atvb.ahajournals.org/content/suppl/2007/02/15/ATVBAHA.107.139881.DC1.html
Data Supplement (unedited) at:
  
 http://atvb.ahajournals.org//subscriptions/
at: 
is onlineArteriosclerosis, Thrombosis, and Vascular Biology  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Question and Answer
Permissions and Rightspage under Services. Further information about this process is available in the
which permission is being requested is located, click Request Permissions in the middle column of the Web
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for 
 can be obtained via RightsLink, a service of theArteriosclerosis, Thrombosis, and Vascular Biologyin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at UniversitÃ  degli Studi di Milano on July 10, 2012http://atvb.ahajournals.org/Downloaded from 
Simvastatin Reduces MMP1 Expression in Human Smooth
Muscle Cells Cultured on Polymerized Collagen by
Inhibiting Rac1 Activation
Nicola Ferri, Giulia Colombo, Corrado Ferrandi, Elaine W. Raines, Bodo Levkau, Alberto Corsini
Objective—Activation of collagen receptors expressed by smooth muscle cells induces matrix metalloproteinase (MMP)
expression. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to interfere
with integrin signaling, but their effects on collagen receptor-mediated MMP expression have not been investigated.
Methods and Results—In the present study, we show that simvastatin (3 mol/L) reduces MMP1 expression and secretion
in human smooth muscle cells cultured on polymerized type I collagen by 39.911.2% and 36.02.3%, respectively.
Reduced MMP1 protein levels correlate with a similar decrease in MMP1 promoter activity (33.08.9%), MMP1
mRNA levels (37.810.5%), and attenuation of smooth muscle cell collagen degradation (34.26.1%). Meval-
onate, and the isoprenoid derivative geranylgeraniol, precursors of geranylgeranylated proteins, completely prevent the
inhibitory effect of simvastatin on MMP1. Moreover, the protein geranylgeranyltransferase inhibitor GGTI-286
significantly decreases MMP1 expression. Retroviral overexpression of dominant-negative mutants of geranylgerany-
lated Rac1 lead to a reduction of MMP1 protein (50.45.4%) and mRNA levels (97.91.0%), and knockdown of
Rac1 by small interfering RNA downregulates MMP1 expression. Finally, simvastatin reduces GTP-bound Rac1
expression levels in smooth muscle cells cultured on polymerized collagen.
Conclusions—These results demonstrate that simvastatin, by inhibiting Rac1 activity, reduces MMP1 expression and
collagen degradation in human smooth muscle cells. (Arterioscler Thromb Vasc Biol. 2007;27:1043-1049.)
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The integrity of interstitial type I collagen in the fibrouscap that covers the atherosclerotic lesions represents a
critical factor for the clinical sequelae associated with car-
diovascular disease, such as myocardial infarction and
stroke.1,2 Therefore, a pharmacological intervention aimed at
inhibiting extracellular matrix degradation may have benefi-
cial effects on the development of atherosclerotic plaques and
their stability. Extracellular matrix not only provides a
scaffold for mechanical support and tissue organization but
also directly alters cell behavior by influencing proliferation,
migration, differentiation, and gene expression. For example,
smooth muscle cells (SMCs) cultured on polymerized type I
collagen show altered expression of a group of genes includ-
ing matrix metalloproteinase (MMP) 1, type I collagen, and
other extracellular matrix components.3–6 This 3-dimensional
culture system has been developed as an in vitro model that
more closely mimics the in vivo extracellular matrix environ-
ment surrounding SMCs.7 In particular, SMC transmembrane
adhesion receptors for type I collagen of the integrin family
and discoidin domain receptors (DDRs) have been shown to
mediate MMP1 upregulation, MMP2 activation, and inhibi-
tion of collagen biosynthesis.8,9
The 3-hydroxy-3-methylglutaryl hydroxymethylglutaryl
coenzyme A reductase inhibitors (statins), drugs commonly
used to reduce plasma cholesterol levels, have been shown to
directly interfere with the major processes of atherogenesis,
including SMC proliferation and migration,10–12 cholesterol
accumulation in macrophages,13 and endothelial cell activa-
tion.14 Moreover, experimental models of atherosclerosis
have clearly documented the beneficial effect of statins on
fibrous plaque stability.15 This effect primarily has been
attributed to the inhibition of MMP expression,16–19 but the
precise molecular mechanisms remain unclear.
The pleiotropic effects of statins have been proposed to be
dependent on inhibition of the mevalonate (MVA) pathway
that reduces the biosynthesis of cholesterol and a number of
nonsteroidal isoprenoid moieties essential for normal cellular
activity, including farnesyl-pyrophosphate and geranylgeranyl-
pyrophosphate.20 These intermediates serve as important lipid
attachments for the posttranslational modification of a variety of
proteins, including the small GTP-binding protein Ras and
Ras-like proteins, such as Rho, Rac, and Rap.21–23 The Rho
family of GTP-binding proteins include Cdc42, Rac1, and
RhoA, which can regulate the adhesive function of integrins by
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promoting avidity modulation through interaction with their
effectors.24 Thus, statins by inhibiting protein prenylation and
the function of Rho GTP-binding proteins may indirectly regu-
late integrin clustering and function.25 In the present study, we
tested the hypothesis that simvastatin may affect MMP expres-
sion in response to polymerized collagen by interfering with
protein prenylation.
Materials and Methods
For detailed descriptions of the Materials and Methods, please
see supplemental material (available online at http://atvb.
ahajournals.org).
Cell Culture and Collagen Matrix Preparation
Human newborn arterial SMCs were isolated from the thoracic aorta
as previously described.26 SMCs between passages 5 and 11 were
cultured in 0.2% bovine serum albumin/modified Eagle medium on
the surface of 3-dimensional polymerized collagen gels (Vitrogen;
Nutacon BV, Leimuden, the Netherlands; 1.0 mg/mL final concen-
tration) and monomer collagen-coated dishes.27
Results
Simvastatin Inhibits MMP1 Expression in Human
SMCs Cultured on Polymerized Collagen
We have previously demonstrated that polymerized type I
collagen induces MMP1 expression and MMP2 activation in
human SMCs by activating the collagen receptors, 21
integrin, DDR1, and DDR2.3,28,29 In agreement with these
studies, a significant induction of MMP1 expression and
processing from pro-MMP2 to MMP2 is observed in human
SMCs cultured on polymerized collagen compared with
monomer collagen (Figure 1; supplemental Figure I, available
online at http://atvb.ahajournals.org). Because statins have
been shown to interfere with integrin signaling,25,30,31 we
hypothesized that simvastatin may interfere with MMP ex-
pression in response to polymerized collagen. In a first set of
experiments, we exposed SMCs cultured on polymerized
collagen to simvastatin for 24 hours. Increasing concentra-
tions of simvastatin (0.5 to 3 mol/L) significantly reduce
intracellular and secreted MMP1 levels as determined by
Western blot analysis of conditioned media and total cell
lysates. Simvastatin at 3 mol/L reduces MMP1 expression
levels by 39.911.2%, and 36.02.3%, respectively; Figure
1A, 1B). Moreover, both atorvastatin (10 mol/L) and
fluvastatin (3 mol/L) significantly affected MMP1 secretion
from human SMCs, by 53.96.2 and 57.616.6% (supple-
mental Figure II). Under the same experimental conditions,
simvastatin at 3 mol/L reduces pro MMP2 expression levels
at both intracellular (30.63.6%) and extracellular levels
(16.63.4%) (supplemental Figure II). Simvastatin 1.5 and
3 mol/L also significantly affected MMP2 secretion by
51.7510.7 and 50.2510.3%, as assessed by gelatin zy-
mography analysis. Levels of MMP9, which is not normally
expressed by cultured human SMCs, were evaluated at the
same time and no alterations were observed with simvastatin
(supplemental Figure II). These data indicate that simvastatin
significantly affected MMP1 production and secretion from
humans SMCs cultured on polymerized collagen together
with reduced levels of MMP2 in the conditioned media.
Simvastatin Reduces MMP1 mRNA Levels and
Inhibits MMP1 Promoter Activity
To further investigate the inhibitory effect of simvastatin on
MMP1 expression, we measured mRNA levels of MMP1 by
quantitative real-time polymerase chain reaction analysis. In
the presence of 3 mol/L simvastatin, MMP1 mRNA levels
were reduced by 37.810.5% (Figure 2A). Similar results
were obtained with 2 other statins, atorvastatin (10 mol/L)
and fluvastatin (3 mol/L), that significantly reduce MMP1
mRNA levels by 85.16.7% and 93.00.8%, respectively,
in SMCs cultured on polymerized collagen (Figure 2B). The
statin inhibitory effect is caused by decreased MMP1 tran-
scription, as simvastatin reduces MMP1 promoter activity in
luciferase gene reporter assays in a concentration-dependent
manner reaching a 33.08.9% reduction of transcription at
3 mol/L (Figure 2C).
Simvastatin Inhibits MMP1 Expression by
Interfering With the Mevalonate Pathway
Statins have been proposed to interfere with integrin signal-
ing by mechanisms both dependent and independent of the
3-hydroxy-3-methylglutaryl-hydroxymethylglutaryl coen-
zyme A reductase activity,25,30,31 the rate-limiting step of the
MVA pathway. At concentrations where a significant reduc-
tion of MMP1 expression is observed (3 mol/L), simvastatin
completely abrogates de novo cholesterol biosynthesis, as
assessed by [14C]-acetate incorporation into cellular sterols
(Figure 3A). The coincubation of simvastatin with MVA, or
GGOH, a MVA-derived isoprenoid, completely prevents the
Figure 1. Simvastatin inhibits MMP1 expression
and secretion by human SMCs cultured on poly-
merized collagen. MMP1 expression was evalu-
ated by Western blot analysis of total cell lysates
(A) and conditioned media (B). Quantitative den-
sitometric analysis (lower panels) performed with
Gel Doc acquisition system and Quantity One
software (BIO-RAD). *P0.05 by Student t test.
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simvastatin block of MMP1 secretion from human SMCs, as
evaluated by Western blot analysis of conditioned media
(Figure 3B), and by quantitative real-time polymerase chain
reaction (Figure 3C). Similar results were also observed with
fluvastatin by real-time polymerase chain reaction quantifi-
cation (supplemental Figure III). Furthermore, the incubation
of SMCs with a specific protein geranylgeranyl transferase-I
inhibitor, GGTI-286, reduces the amount of secreted MMP1
in human SMCs cultured on polymerized collagen by
53.17.6% at 10 mol/L concentration (Figure 3D). These
results suggest that statins reduce MMP1 expression levels by
interfering with protein geranylgeranylation processes.
Rac1 Regulates MMP1 Secretion From Human
SMCs Cultured on Polymerized Collagen
To further establish the role of geranylgeranylated proteins in
the regulation of MMP1 expression, dominant-negative forms
of RhoA and Rac1 were overexpressed in human SMCs with
HA epitope-tags. Western blot analysis of total cell lysates
shows that N19RhoA and N17Rac1 are efficiently expressed
in human SMCs (data not shown). Whereas N19RhoA
expression in human SMCs cultured on polymerized collagen
has no effect on MMP1 secretion, N17Rac1 significantly
reduced MMP1 expression levels by 50.45.4% (Figure 4A).
MMP1 mRNA levels are also significantly reduced in human
SMCs cultured on polymerized collagen overexpressing
N17Rac1 (97.91.0%) (Figure 4B). Overexpression of
either dominant negative mutants does not affect MMP2
expression and activation in SMCs, as assessed by gelatin
zymography analysis (Figure 4C).
To confirm the role of Rac1 in MMP1 expression, SMCs
were transfected with siRNA against Rac1 and control
siRNA, and MMP1 expression was evaluated by Western blot
analysis of conditioned media. A marked reduction of Rac1
Figure 2. MMP1 mRNA expression and promoter
activity is inhibited by simvastatin in human
SMCs cultured on polymerized collagen. A and
B, MMP1 mRNA levels were determined by
quantitative real-time polymerase chain reaction
analysis. *P0.05, **P0.01, ***P0.001 by Stu-
dent t test. C, MMP1 promoter activity was eval-
uated in human SMCs retrovirally infected with
pBM-SIN-proMMP1-luciferase constructs.
*P0.05 by Student t test. The data are repre-
sentative of 2 independent experiments.
Figure 3. MMP1 expression in human SMCs cul-
tured on polymerized collagen is dependent on
protein geranylgeranylation. A, Cholesterol bio-
synthesis was determined by measuring the
incorporation of [14C]-Acetate into cellular sterols.
***P0.001, simvastatin vs control by Student t
test. B and C, Human SMCs were cultured on
polymerized collagen in the presence or absence
of 3 mol/L simvastatin coincubated with
100 mol/L mevalonate (MVA) and 2.5 mol/L
geranylgeraniol (GGOH). MMP1 protein (B) and
mRNA levels (C) were evaluated by Western blot
analysis of conditioned media, and quantitative
real-time polymerase chain reaction of total RNA,
respectively. *P0.05 simvastatin vs control;
†P0.001 simvastatin plus MVA vs simvastatin;
‡P0.001 simvastatin plus GGOH vs simvastatin
by Student t test. D, Effect of GGTI-286 was
tested on human SMCs cultured on polymerized
collagen. MMP1 expression was determined by
Western blot analysis of conditioned media (D).
Quantitative densitometric analysis of (D).
*P0.05; **P0.01 by Student t test (lower panel).
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protein expression is observed after Rac1 siRNA treatment
that is associated with reduced secretion of MMP1 from the
cells in response to polymerized collagen, as compared with
SMCs transfected with control siRNA (Figure 4D).
These results indicate that activation of Rac1 is necessary
to induce MMP1 expression in human SMCs in response to
polymerized collagen, and support the possibility that simva-
statin may inhibit MMP1 expression through the blockade of
protein geranylgeranylation. To directly address this question
we investigated the effect of simvastatin on the activation
state of Rac1. Total cell lysates were prepared from SMCs
cultured on polymerized collagen in the presence or absence
of 3 mol/L simvastatin. Active Rac1 was precipitated with
the PBD domain of human PAK1 fused to glutathione
S-transferase, and total Rac1 were determined by Western
blot analysis. As shown in Figure 4E, simvastatin strongly
reduces Rac1 activity in SMCs cultured on polymerized
collagen, in spite of simvastatin upregulation of Rac1 expres-
sion in SMCs cultured on polymerized collagen.
Simvastatin Reduces the Collagen Degrading
Activity of Human SMCs
To evaluate whether the simvastatin-mediated reduction of
MMP1 expression is sufficient to affect the degradative and
remodeling activities of human SMCs, we measured levels of
MMP inhibitors and the release of collagen fragments into the
media of SMCs cultured on fluorescein isothiocyanate-
labeled polymerized collagen. Simvastatin does not effect the
expression of endogenously expressed inhibitors TIMP1 and
reversion-inducing cysteine-rich protein with Kazal motifs,32
and only slightly reduces TIMP2 expression levels (Figure
5B).33 Simvastatin at 3 mol/L inhibited SMC collagen
degradation by 34.26.1%, whereas the broad MMP inhibi-
tor GM-6001 led to 57.61.5% reduction (Figure 5A). This
effect strongly correlated with MMP1 expression levels
(Figure 5C).
Discussion
Rac1 Is the Primary Intracellular Target of
Simvastatin-Mediated Reduction of MMP1
Expression in Response to Polymerized Collagen
We have previously shown that integrin and DDR-mediated
adhesion of SMCs to polymerized collagen induces MMP1
expression and collagen degradation.3,28,29 In the present
study, we investigated the effect of simvastatin on this
cellular response and show that the inhibition of the MVA
pathway with a subsequent inactivation of Rac1 leads to the
reduction of MMP1 expression induced by polymerized
collagen (supplemental Figure IV). The demonstration that
the effect of simvastatin on MMP1 expression is dependent
on the inhibition of protein geranylgeranylation is supported
by the evidence that geranylgeraniol, a substrate of protein
Figure 4. Simvastatin inhibits Rac1 activity that regu-
lates MMP1 expression in human SMCs cultured on
polymerized collagen. MMP1 (A) and MMP2 (C) pro-
tein expression were determined from conditioned
media and mRNA (B) from cell lysates of human
SMCs transduced with pBM-IRES-PURO retrovirus
encoding control vector (PURO), 19NRhoA, or
17NRac1. Quantitative densitometric analysis is
shown in lower panel (A). **P0.01 by Student t test.
B, MMP1 mRNA levels were determined by quantita-
tive real-time polymerase chain reaction analysis.
***P0.001 by Student t test. C, Conditioned
medium containing MMP9, pro-MMP2, and MMP2
was used as standard control (St). All the data are
representative of 2 independent experiments. D,
Human SMCs were transfected with specific siRNA
against Rac1 or nonsilencing control siRNA, and
Rac1 expression was evaluated by Western blot
analysis after 24 hours of cultured on polymerized
collagen. Conditioned media was collected and
MMP1 expression evaluated by Western blot analy-
sis. E, GTP-bound and total Rac1 expression was
determined by Western blot analysis of total cell
lysates of human SMCs cultured on polymerized col-
lagen for 24 housr in the presence or absence of
3 mol/L simvastatin.
Figure 5. MMP-mediated collagen degradation is inhibited by
simvastatin. A, Human SMCs were cultured on fluorescein
isothiocyanate-polymerized collagen in the presence or absence
of the MMP inhibitor GM6001 and indicated concentrations of
simvastatin for 24 hours. Release of fluorescein isothiocyanate-
collagen fragments was measured by fluorimetric analysis.
**P0.01 and **P0.001 by Student t test. B, TIMP1, TIMP2,
and (C) MMP1 expression were evaluated by Western blot anal-
ysis of conditioned media of SMCs cultured in the presence or
absence of 3 mol/L simvastatin, and reversion-inducing
cysteine-rich protein with Kazal motifs (B) from total cell lysates.
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geranylgeranyltransferases, completely restores protein and
mRNA levels blocked by simvastatin, and that the protein
geranylgeranyl transferase-I inhibitor GGTI-286 significantly
inhibits MMP1 secretion. We therefore hypothesized that one
or more geranylgeranylated protein(s) may be involved in this
process.
Among several prenylated proteins, the Rho family of
GTPases is the best characterized, and several studies have
implicated the Rho family in the regulation of MMP1
expression. For example, it has been reported that Rac1
activity is required for the induction of MMP1 mediated by
inactivation of the 51 integrin.34 Moreover, downregula-
tion of Cdc42 by siRNA led to upregulation of MMP1 in
human skin fibroblasts, an effect that required the presence of
Rac1.35 Our studies extend Rac1 involvement to normal
human SMCs with the demonstration that overexpression of
the dominant-negative mutant of Rac1, or suppression of
Rac1 expression with siRNA, is sufficient to prevent the
upregulation of MMP1 on polymerized collagen.
The dependence of simvastatin’s action on Rac1 inhibition
is also supported by the levels of active Rac1 in cells cultured
on polymerized collagen. Rac1 activity is strongly inhibited
by simvastatin, an effect most likely caused by a reduction in
the intracellular availability of geranylgeranyl-PP. Thus, we
conclude that Rac1 represents one of the simvastatin’s intra-
cellular targets, and its inhibition suppresses MMP1 expres-
sion (supplemental Figure IV). Moreover, we showed that
simvastatin reduces the collagenolytic activity of human
SMCs, by shifting the MMP/MMP inhibitors balance. Indeed,
simvastatin strongly reduces MMP1 and MMP2 extracellular
levels without affecting the expression of tissue inhibitor of
metalloproteinse (TIMP)-1 reversion-inducing cysteine-rich
protein with Kazal motifs,32 and only slightly reduces
TIMP-2 levels.33
Statins have been previously shown to reduce the expres-
sion of MMP1, MMP2, and MMP9 in human saphenous vein
SMCs stimulated with a combination of PDGF-BB and
IL1-.17,36 The effect on MMP9 was probably caused by the
inhibition of the RhoA/ROCK pathway because the Rho-
kinase (ROCK) inhibitor Y27632 also decreased MMP9
secretion,36 while the inhibitory effect of lovastatin on MMP1
and MMP2 expression was prevented by the addition of
geranylgeranyl-PP suggesting the involvement of prenylated
proteins.17 Moreover, the inhibition of Rho proteins by C3
exoenzyme has been shown to decrease the basal secretion of
MMP1 from human umbilical endothelial cells,18 indicating
the involvement of a small GTP-binding protein(s). The
present study specifically identifies Rac1 as the primary Rho
family GTPase responsible for MMP1 induction after the
SMC collagen receptor engagement on polymerized collagen.
Further studies will be required to determine the role of Rac1
and/or other RhoA in MMP1 expression in response to
platelet-derived growth factor (PDGF)-BB and IL-1 from
human SMCs. Moreover, simvastatin significantly reduced
pro MMP2 levels and MMP2 secretion, but the involvement
and the identification of intracellular prenylated proteins
responsible for this action still needs to be determined. In
fact, the expression of both RhoA and Rac1 dominant-
negative mutants did not affect MMP2 expression levels, as
assessed by gelatin zymography analysis.
Simvastatin Inhibits MMP1 Transcription by
Interfering With Collagen Receptor Signaling
The adhesion of SMCs to polymerized collagen is primarily
mediated by 21 integrin and DDRs,8,9 and both receptor
families have been shown to upregulate MMP1.3,5,29 The
hypothesis that simvastatin may inhibit this cellular response
was based on previous findings that integrin signaling can be
affected by statins in different ways.25,30,31 The best-
understood molecular mechanisms of integrin blockade by
statins are the alteration of integrin clustering and activation
through the inhibition of the prenylation and functional
modulation of Rho family of GTPases.25 However, statins
have also been shown to upregulate 21 integrin expression
in human SMCs, and to increase cell adhesion to collagen,
effects reversed by MVA and geranylgeraniol.30 In our study,
we did not observe any significant change in either SMC
adhesion to polymerized collagen or cell-surface expression
of 21 integrin in response to simvastatin (data not shown).
These data suggest that simvastatin is unlikely to alter
cell–collagen interactions by directly binding the I domain of
2 integrin subunit, as previously described for the leukocyte
function antigen-1 in T-cells.31 Furthermore, the interaction
of statins with integrin I domain was shown to be independent
of its action on 3-hydroxy-3-methylglutaryl-hydroxymeth-
ylglutaryl coenzyme A reductase, whereas our study demon-
strates that MVA completely rescues simvastatin-mediated
suppression of MMP1. Thus, our data indicate that simvasta-
tin may affect 21 integrin and/or DDR signaling by
interfering with small GTP-binding protein activity and
receptor and/or DDR clustering.
MMP1 expression in response to collagen-receptor en-
gagement is regulated at the transcriptional level, and nuclear
factor -B (NF-B) plays a major role in MMP1 transcrip-
tion.3,5 Although the presence of a putative responsive NF-B
elements on human MMP1 promoter is still unclear,3,37 we
demonstrate that simvastatin inhibits MMP1 promoter activ-
ity. The inhibition of MMP1 transcription by simvastatin
appears to be mediated by Rac1 blockade. Expression of
MMP1 mRNA is significantly reduced by the expression of a
dominant-negative Rac1, and MMP1 expression is com-
pletely restored by co-incubation with geranylgeraniol. The
effect of simvastatin on NF-B activation in our cell culture
model still needs to be determined, but statins have been
previously shown to inhibit NF-B activation in endothelial
cells.38 Because Rac1 is a potent inducer of NF-B transcrip-
tional activity,39 it is conceivable that simvastatin may de-
crease MMP1 expression by affecting NF-B activity.
Potential Implications of Statin-Mediated
Inhibition of Smooth Muscle Integrin-Dependent
Collagen Remodeling
Culture systems using collagen gels have been developed to
more closely resemble the cell–matrix interactions observed
in vivo in fibroproliferative disorders, including atheroscle-
rosis.4 One limitation of this cell–culture system is that SMCs
change their integrin expression from the 1 to 2 subunit
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when isolated from vessels and placed in culture.40 In fact,
vascular SMCs in the media of normal arteries only express
11 integrin with no detectable 21.40,41 However, both
11 and 21 integrins have been implicated in collagen
remodeling,4,41 and pharmacological interference with both
receptors may alter extracellular matrix degradation.
The casual contribution of 11 integrin to the develop-
ment of lesions of atherosclerosis in vivo have been recently
shown: genetic deletion of 11 integrin in apolipoprotein
E-deficient mice led to a reduction of atherosclerotic plaque
formation associated with an increase in collagen deposi-
tion.42 Further, atherosclerotic lesions of apolipoprotein
E-deficient mice treated with anti 1 integrin antibody
showed increased collagen content.42 Thus, inhibition of
11 integrin shifted plaque composition to a more stable
phenotype, with increased collagen and SMC content. Our
study shows that simvastatin strongly suppresses the induc-
tion of MMP1 and SMC collagenolytic activity dependent on
collagen receptors. We propose that this mechanism may
contribute to the ability of statins to stabilize lesions of
atherosclerosis.
In conclusion, we show that the adhesion of human SMCs
to polymerized collagen, through 21 integrin, and the
DDRs upregulate MMP1 expression and collagen degrada-
tion by a mechanism dependent on Rac1 activity. Simvastatin
and the protein geranylgeranyltransferase-I inhibitor GGTI-
286 interfere with this signaling pathway, thus leading to a
reduction of MMP1 expression and collagen degradation in
human SMCs (supplemental Figure IV).
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